Spotlight on Eureka Nanobioengineering: Redefining Modular Biologics

This week, we're putting the spotlight on a biotech redefining what a modular biologics platform can look like: Eureka Nanobioengineering. At INBISTRA, we are proud to be supporting them in a strategic advisory capacity.

Eureka Nanobioengineering is an early-stage biotech company based in Argentina, founded by Damian Alvarez Paggi, Daniel H. Murgida, PhD, and Salvador Ventura, an exceptionally strong team with deep scientific expertise across protein engineering, structural biology, immunology, and vaccinology. The company is advancing a proprietary platform based on self-assembling nanobiomaterials that can carry different active components depending on the medical need.

The same core technology can be configured to deliver vaccine antigens, power diagnostic tools, or trigger immune responses for therapy. What makes it distinctive is that the underlying architecture never changes, only what it carries does, adapting the functional component to the intended use. One platform, multiple products, across some of the most pressing areas in global health. The technology has the modularity to support multiple development paths under a genuine One Health vision, something we strongly value at INBISTRA.

“Over the past months, we have had the opportunity to work closely with the Eureka NBE team. Eureka is an innovative company seeking to disrupt the biologics field by establishing themselves as the de facto platform for the modular design of novel therapeutics. I have been honestly impressed by their ‘LEGO-like’ approach to building novel complex antigenic responses, and I am very much looking forward to expanding our collaboration,” says Ignacio Sancho-Martinez, PhD, Managing Partner of INBISTRA.

As Eureka Nanobioengineering prepares to set up operations in Europe, we are committed to contributing to this stage of their journey and look forward to their continued progress and success.